Optimer's Dificid Cleared Down Under - Analyst Blog

By
A A A

Optimer Pharmaceuticals ( OPTR ) received encouraging news recently when the Australian regulatory body (Australian Therapeutic Goods Administration) cleared its drug Dificid (fidaxomicin). Dificid tablets were cleared for the treatment of confirmed clostridium difficile infection (CDI) in adults.

The product will be available in Australia from May 14, 2013 from Specialised Therapeutics Australia Pty, Ltd. (STA). We note that STA has the exclusive rights to Dificid in Australia and New Zealand.

Dificid's Australian approval was based on positive results from two phase III studies evaluating the safety and efficacy of the drug in comparison to ViroPharma Inc.'s ( VPHM ) oral Vancocin in CDI patients.

We remind investors that Dificid, Optimer's sole marketed product, was launched in the US in Jul 2011 for treating patients suffering from clostridium difficile-associated diarrhoea (CDAD) -- the most common symptom of CDI. Dificid was launched in Canada in Jun 2012. Dificid is also approved in the EU under the trade name, Dificlir, since Dec 2011.

Optimer has an exclusive agreement with Astellas Pharma ( ALPMY ), under which Astellas has the rights to develop and commercialize Dificid in Europe and certain other countries. In Mar 2012, Optimer entered into another collaboration and license agreement with Astellas Japan. Astellas was granted exclusive, royalty-bearing license and intellectual property to develop and commercialize Dificlir in Japan.

Optimer reported Dificid net product sales of $62.4 million in the US in 2012 compared to $21.5 million in 2011.

While we are pleased with the company's effort to expand Dificid's market globally, we remain concerned about Optimer's dependence on a single product for growth.

Optimer, a biopharma company, currently carries a Zacks Rank #3 (Hold). Meanwhile, other biopharma stocks such as Incyte Corp. ( INCY ) currently look better positioned carrying a Zacks Rank #1 (Strong Buy).



ASTELLAS PHARMA (ALPMY): Get Free Report

INCYTE CORP (INCY): Free Stock Analysis Report


OPTIMER PHARMAC (OPTR): Free Stock Analysis Report

VIROPHARMA (VPHM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: ALPMY , CDI , INCY , OPTR , VPHM

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Visualizing Healthcare MG
Visualizing Healthcare MG           
Power on/Power Off IPC
Power on/Power Off IPC              
Spot the Dropout RRC
Spot the Dropout RRC                
Power on/Power Off
Power on/Power Off                  

Stocks

Referenced

100%
50%

Most Active by Volume

105,858,039
  • $10.50 ▲ 3.04%
105,433,684
  • $29.22 ▲ 4.62%
72,716,790
  • $16.36 ▼ 0.49%
51,381,067
  • $113.29 ▲ 0.33%
47,443,661
  • $2.39 ▲ 4.82%
45,387,229
  • $5.78 ▲ 0.87%
45,001,566
  • $105.62 ▼ 0.02%
42,379,286
  • $28.42 ▲ 2.53%
As of 8/28/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com